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Aims Recent immunohistochemical studies observed the loss of plakoglobin (PG) from the intercalated disc (ID) as a hall-
mark of arrhythmogenic right ventricular cardiomyopathy (ARVC), suggesting a ﬁnal common pathway for this
disease. However, the underlying molecular processes are poorly understood.
Methods and
results
We have identiﬁed novel mutations in the desmosomal cadherin desmocollin 2 (DSC2 R203C, L229X, T275M, and
G371fsX378). The two missense mutations (DSC2 R203C and T275M) have been functionally characterized,
together with a previously reported frameshift variant (DSC2 A897fsX900), to examine their pathogenic potential
towards PG’s functions at the ID. The three mutant proteins were transiently expressed in various cellular
systems and assayed for expression, processing, localization, and binding to other desmosomal components in com-
parison to wild-type DSC2a protein. The two missense mutations showed defects in proteolytic cleavage, a process
which is required for the functional activation of mature cadherins. In both cases, this is thought to cause a reduction
of functional DSC2 at the desmosomes in cardiac cells. In contrast, the frameshift variant was incorporated into
cardiac desmosomes; however, it showed reduced binding to PG.
Conclusion Despite different modes of action, for all three variants, the reduced ability to provide a ligand for PG at the desmo-
somes was observed. This is in agreement with the reduced intensity of PG at these structures observed in ARVC
patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heart
muscle disorder associated with heart failure, ventricular
arrhythmias,
1,2 and sudden death.
3 Familial disease occurs in 30–50%
of the cases with usually autosomal-dominant inheritance. Mutations
in ﬁve cardiac desmosomal genes have been identiﬁed,
2 founding the
hypothesis that ARVC is a ‘disease of altered cell–cell adhesion’.
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within the intercalated disc (ID), which allow the heart to withstand
mechanical strain during contractile cycles. In these structures, the
desmosomal cadherins desmoglein-2 (DSG2) and desmocollin-2
(DSC2) link neighbouring cells via interactions with their extracellu-
lar cadherin domains.
4 The intracellular portions of both proteins
interact with plakoglobin (PG) and plakophilin-2 (PKP2), which in
turn bind desmoplakin (DSP), therefore providing a link to inter-
mediate ﬁlaments.
5
At the histological level, ARVC is characterized by a progressive
replacement of cardiomyocytes by ﬁbro-fatty inﬁltrates.
6 Recently,
the loss of PG immunoreactivity from the ID has been suggested as
a highly speciﬁc and sensitive marker for the disease.
7 In this study,
almost all cardiac tissues from ARVC patients showed a loss of PG
from the ID, independent of the affected gene. Equally important,
this loss of PG staining was not observed in tissues of other cardiac
conditions. Although this highlights the diagnostic value of this test
for deﬁning ARVC in patients, the molecular changes underlying the
phenomenon are yet to be identiﬁed.
So far, functional studies have mainly focused on the role of DSP,
PKP2, and PG to elucidate potential patho-mechanisms of ARVC.
8–11
Mutations in both cardiac desmosomal cadherins, DSG2 and DSC2,
also contribute to the disease.
2,12–14 The crucial function of DSC2
for the heart was demonstrated by knock-down experiments in the
zebraﬁsh model.
15 DSC2 is expressed as two different splice variants
with different Carboxy-termini.
16 The DSC2a isoform has a larger
cytoplasmic domain than the DSC2b isoform; however, the differential
functionsofthetwoisoformsinthemyocardiumarenotwellcharacter-
ized. Interestingly, the DSC2 A897fsX900 variant
17 only affects the
DSC2a, but not the DSC2b isoform. This variant was initially found in
ARVC families, where it co-segregated with disease (referred to as
DSC2 E896fsX900 in Syrris et al.
17). However, it has now also been
identiﬁed in apparently healthy individuals,
18 disputing its causative
role in ARVC.
Here, we describe four novel mutations in DSC2 causing ARVC.
Two of them are predicted to be non-functional alleles. In contrast,
the characteristics of the two missense mutations are to be deﬁned.
To do so, we perform functional studies on these two mutations
and also include the previously described DSC2 A897fsX900 variant
in our tests. Our experiments demonstrate a pathogenic potential
of all three mutations analysed. Despite the different properties of
the mutant proteins, one common feature was observed in all
cases: a reduced ability to retain PG at the cardiac desmosomes.
This may play a pivotal role in the pathogenesis of the disease.
2. Methods
2.1 Clinical evaluation and mutation screening
Informed consent was obtained from the participating individuals and the
study was approved by the Joint UCL/UCLH Ethics Committees, Research
and Development Directorate (ref. no. 03/0306). The investigation con-
forms with the principles outlined in the Declaration of Helsinki.
Genetic screening of DSP, PG, PKP2, DSG2, and DSC2 by direct sequen-
cing and clinical evaluation were performed as described previously.
19 The
latter included 12-lead electrocardiogram (ECG), signal-averaged ECG
with 40 Hz ﬁlter, two-dimensional echocardiography, maximal exercise
testing, ambulatory ECG monitoring, and coronary angiography (where
needed). The diagnosis of ARVC was based on the recent revision of
the original criteria proposed by the International Task Force of the





Myocardial tissue of Patient 55.2 was probed for changes in the localiz-
ation of desmosomal proteins by immunoﬂuorescence and confocal
microscopy as described
21 using the following antibodies: polyclonal
rabbit anti-connexin 43 (Cx43) (Sigma), monoclonal mouse anti-PG
(Sigma), polyclonal rabbit anti-DSP (SeroTec), monoclonal mouse
anti-N-cadherin (Sigma), and monoclonal mouse anti-PKP2 (BioDesign).
2.3 Generation of cDNA constructs
A full-length human DSC2a wild-type (WT) cDNA was kindly provided by
Prof. W. Franke (German Cancer Research Center, Heidelberg, Germany)
and cloned into pEGFP-N1 (Clontech) and pCDNA3 (Invitrogen). The
mutations (R203C, T275M, and A897fsX900) were introduced by site-
directed mutagenesis (Quikchange kit, Stratagene). Human sequences
corresponding to cytoplasmic regions of DSC2a WT (aa 716–901),
A897fsX900 (aa 716–899), DSC2b (aa 716–847), and DSG2 (aa 635–
842) were cloned into pGEX6P1 (GE Healthcare) and mammalian
expression vector pEBG
22 (a kind gift of Dr Alan Whitmarsh, University
of Manchester, UK).
2.4 Antibodies
The following antibodies were for functional studies: a mouse monoclonal
antibody (mAB) against green ﬂuorescent protein (GFP, Roche), desmo-
collin2/3 mAB (clone 7G6, Zymed), PG mAB (clone 15/g-Catenin BD
Biosciences), desmoglein1/2 (clone DG3.10, Progen), PKP2 mAB (multi-
epitope cocktail, Progen), giantin mAB (Golgi apparatus marker
23).
b-Catenin (Sigma), DSC2 (Sigma, Prestige Antibody Ab2, HPA012615)
and DSP (Serotec) polyclonal rabbit, and anti-GST polyclonal goat anti-
bodies were also used. Sheep-anti-mouse IgG antibody (GE Healthcare)
and rabbit-anti-goat IgG antibody (Pierce), both conjugated to horseradish
peroxidase, were used for the detection of primary antibodies in western
blotting.
2.5 Cell culture and transfections
COS-1 cells were cultured and transfected with Escort IV (Sigma) as
described,
24 using 7.5 mg of each DNA construct in 10 cm dishes.
The atrial cell line HL-1 (a kind gift of Dr R. Breckenridge, Centre for
Clinical Pharmacology, University College London, UK) was cultured in
Claycomb medium (Sigma), supplemented with 10% foetal bovine
serum (Sigma), 2 mM L-glutamine (Gibco), 100 U/mL penicillin, 100 mg/
mL streptomycin (Gibco), and 100 mM noradrenalin (Sigma). HL-1 cells
were transfected with 4 mg of DNA and Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.
Primary cultures of neonatal rat cardiomyocytes (NRC) were estab-
lished using the Neonatal Cardiomyocyte Isolation System from
Worthington (Lakewood, NJ, USA). The use of the neonatal rats was in
accordance with the NIH guidelines. The cells were plated, maintained,
and transfected on day 1 after plating using 5 mg of DNA and JetPrime
transfection reagent (Autogen Bioclear) as described.
13 All transfected
cells were analysed for expression of the recombinant proteins 48 h
after transfection. Indirect immunoﬂuorescence and confocal microscopy
were performed as described.
13
2.6 GST-pulldown assays
Expression of GST fusion proteins in BL21 Codon Plus strain (Stratagene)
and puriﬁcation with glutathione–sepharose beads (GE Healthcare) has
been described elsewhere.
13 Protein-loaded beads were incubated with
pre-cleared adult rat heart lysate (350 mg total protein) in GST-pulldown
buffer for 1 h on ice. After washing three times with GST-pulldown buffer,
K. Gehmlich et al. 78the bound proteins were eluted with two-fold SDS sample buffer. GST
fusion proteins were analysed by SDS–PAGE and visualized with Instant-
Blue (Generon), and western blotting was performed to probe for bound
PG and PKP2.
Detailed descriptions of the experiments (including buffer solution
compositions) can be found in the Supplementary material online.
3. Results
3.1 Identiﬁcation of novel DSC2 mutations
in ARVC patients
Genetic screening of DSC2 revealed a single heterozygous change in
exon 5 (c.607 C . T) in a Caucasian ARVC patient (family 35), coding
for an arginine to cysteine missense change at position 203 (DSC2
R203C, Figure 1A and see Supplementary material online, Table S1).
In addition, a further heterozygous missense change in DSP (c.5498
A . T coding for E1833V) was identiﬁed in the index patient
(35.1). A recent study has suggested a frequency of 1.5% for this poly-
morphism.
25 In the same family, the DSC2 R203C mutation was also
found in Individual 35.3, who was negative for the DSP E1833V
variant. He had a borderline diagnosis for ARVC
20 (see Supplemen-
tary material online, Table S1). His available siblings (35.2 and 35.4)
were negative for the DSC2 mutation and clinically normal; one of
them (35.4) carried the DSP E1833V variant.
In another ARVC patient (37.1), a homozygous change in exon 7 (c.
824 C . T) was found, predicting a threonine to methionine missense
change at position 275 (DSC2 T275M, Figure 1B). Both daughters of
the index patient (37.2 and 37.3) were heterozygous for the DSC2
T275M mutation and asymptomatic. One of them (37.3) was available
for clinical testing and clinically normal.
In family 53, a heterozygous deletion of one base pair was found in
exon 6 (c. 685 delC), which predicts a premature Stop codon at pos-
ition 229 (DSC2 L229X, Figure 1C). The index patient (53.1) also
carried a benign, heterozygous PKP2 A372P variant.
26 His brother
(53.2) also fulﬁlled diagnostic criteria for ARVC in the presence of
the DSC2 L229X mutation, whereas the son (53.3) was clinically unaf-
fected in the presence of the mutation.
Finally, a two-base pair deletion was found in exon 9
(c.1112_1113delTG) in family 55 (Individual 55.1). This heterozygous
change predicts a frameshift at amino acid 371, leading to a premature
stop at position 378 (DSC2 G371fsX378, Figure 1D). The son (55.2)
had died suddenly at the age of 35 and diagnosis of ARVC was con-
ﬁrmed histologically at post-portem (see Supplementary material
online, Figure S5A) in the presence of the mutation. His sister (55.3)
was negative for the DSC2 mutation and clinically normal. The
sister of the index patient (55.4) did not fulﬁl diagnostic criteria for
ARVC in the presence of the mutation.
None of the DSC2 mutations was found in 200 control individuals.
No further changes were found in PKP2, PG, DSG2, or DSP in these
families.
3.2 Functional studies on ARVC-associated
DSC2 mutations
The novel mutations DSC2 L229X and DSC2 G371fsX378 are pre-
dicted to generate non-functional alleles: The truncated proteins, if
expressed at all, cannot be anchored in the plasma membrane
(Figure 2A). In contrast, the newly identiﬁed missense mutations
DSC2 R203C and DSC2 T275M only change a single amino acid in
the extracellular domains of the protein (Figure 2A), whereas the
DSC2 A897fsX900 variant also only affects a small portion of the
cytoplasmic domain (namely the last ﬁve amino acids of the DSC2a
isoform, Figure 2A; see Supplementary material online, Figure S1A).
We speculated that these different variants may contribute to the
same disease mechanism. To understand the pathogenic action of
DSC2 R203C, DSC2 T275M, and DSC2 A897fsX900, all three
mutations were introduced into a DSC2a cDNA and functionally
characterized.
3.3 Impaired proteolytic processing of
N-terminal DSC2 mutations
The mutant proteins were expressed in COS-1 cells and analysed by
western blotting in comparison to their WT counterpart: the DSC2
WT protein was detected predominantly in its cleaved, mature
form (‘M’ in Figure 2B,  90% Figure 2C) and only small amounts of
the un-cleaved precursor form could be detected (‘P’ in Figure 2B,
 10%, Figure 2C; see Supplementary material online, Figure S2). The
same ratio was observed for the A897fsX900 mutation. In contrast,
the DSC2 R203C protein was exclusively detected in the unpro-
cessed pro-protein form, and the DSC2 T275M showed a signiﬁcantly
higher ratio of pro-protein to mature protein (Figure 2B and C; see
Supplementary material online, Figure S2).
These ﬁndings suggest that while the vast majority of DSC2 WT
and A897fsX900 are correctly processed into their active form, the
T275M protein is impaired in this maturation process and the
R203C protein completely fails to undergo it.
3.4 Partial or severe defects in desmosomal
localization of N-terminal DSC2 mutations
As a next step, we investigated the localization of the three DSC2
mutants in the cardiac cell line HL-1. Transiently transfected DSC2
WT showed predominant localization at cell borders (Figure 3; also
see Supplementary material online, Figure S1B); higher magniﬁcation
showed a dotted appearance of the DSC2 protein at the sites of
cell–cell contacts, indicating incorporation into desmosomes.
27
Depending on the expression level, part of the over-expressed
protein was additionally found in the Golgi apparatus and in intracellu-
lar vesicles. The localization of the DSC2 A897fsX900 variant was
similar to WT protein, with a slight shift from cell border to Golgi
apparatus localization (Figure 3B). This suggests that this variant can
be incorporated into desmosomes. The DSC2 R203C protein failed
to localize at the cell borders and was absent from desmosomal struc-
tures. Instead, it was diffuse or localized in vesicles throughout the
cytoplasm of the HL-1 cells. Although the DSC2 T275M protein
was able to localize in the desmosomes, a shift towards vesicular
and Golgi apparatus localization was observed (Figure 3B).
In primary cardiomyocytes, DSC2 WT was almost exclusively
found at the ID, where it co-localized with recognized ID markers
such as b-catenin (Figure 4). In agreement with our HL-1 studies,
the DSC2 A897fsX900 protein was also found to be normally incor-
porated into the ID (Figure 4B). Only a very small fraction of DSC2
R203C was targeted to the ID structures, most of the protein was
found in cytoplasmic vesicles (Figure 4; see Supplementary material
online, Figure S3). The DSC2 T275M mutation was found at the ID,
although to a lesser extent than the WT protein, and showed
additional vesicular localization in the cytoplasm.
DSC2 mutations causing ARVC 793.5 The DSC2a A897fsX900 variant
is impaired in binding to PG
Our localization studies demonstrated that the DSC2 A897fsX900
variant is incorporated into the desmosomes similar to the DSC2
WT protein, whereas the N-terminal missense mutations are impaired
or defective in this process. Therefore, the DSC2 A897fsX900 variant
appears to have different characteristics, and any pathogenic potential
of this variant should be an adverse action at the desmosomes, most
likely by affecting binding properties of the intracellular, cytoplasmic
domain, which links DSC2 to PG and PKP2.
5
To explore the nature of this variant in more detail, we performed
binding assays to investigate how the cytoplasmic tails of all cardiac
desmosomal cadherins, namely DSC2a, DSC2b, and DSG2, contrib-
ute to binding PG and PKP2 (Figure 5A). Using rat heart lysates,
GST fusion proteins of all three pulled out PKP2, whereas only
DSC2a and DSG2 bound to PG. This suggests that the binding sites
of PG and PKP2 might be distinct. Interestingly, the DSC2
A897fsX900 variant bound normally to PKP2; however, its binding
to PG was reduced by  50%.
To conﬁrm these ﬁndings, GST fusion proteins of the cytoplasmic
tail of DSC2a WT and A897fsX900 were expressed in COS-1 cells
Figure 1 Identiﬁcation of novel mutations in DSC2 in Caucasian families. Pedigrees of the families with novel DSC2 mutations: black symbols, fulﬁls
diagnostic criteria for ARVC
20; white symbols, does not fulﬁl TFC; grey symbol, borderline ARVC diagnosis; question mark, unknown disease status.
Slanted bars, deceased individuals; squares, males; circles, females; plus (+) and minus (2) indicate the presence or absence of the DSC2 mutation;
arrow, index patient; for details, see Supplementary material online, Table S1. The pedigrees of the families are shown on the left, the sequence elec-
tropherograms on the right (open arrows indicate mutations in comparison to WT individuals). (A) A heterozygous DSC2 R203C mutation in family
35 (C   T change at nucleotide position 607). (B) Family 37: Individual 37.1 is homozygous for DSC2 T275M (C   T change at nucleotide position
824), whereas Individual 37.2 is heterozygous for the same change. (C) In family 53, a heterozygous deletion of C at nucleotide position 685 causes
DSC2 L229X. (D) A heterozygous two-base pair deletion was identiﬁed in family 55 (c.1112_1113delTG), resulting in DSC2 G371fsX378.
K. Gehmlich et al. 80and assayed for binding to endogenous PKP2 and PG. As shown in
Figure 5B, the DSC2a A897fsX900 protein showed a dramatically
reduced binding to PG, whereas binding to PKP2 was only mildly
affected.
Binding to DSP was assessed using the N-terminal portion of this
protein. Only DSC2a WT bound to this protein fragment, no
binding of DSC2b was observed. The binding of DSC2 A897fsX900
was weaker in comparison to DSC2a WT ( 50%, Figure 5C).
3.6 The DSC2 mutations affect
desmosomal PG
We observed the loss of PG signal from the ID in the myocardium of
an individual (55.2) with the DSC2 G371fsX378 null mutation
(Figure 6A; other desmosomal components in Supplementary material
online, Figure S5B). In the absence of patient material for the other
mutations, co-immunoprecipitation experiments were performed
with full-length DSC2a constructs. In agreement with its non-
functional state, binding of DSC2 R203C to PG and PKP2 was
reduced (Figure 6B). In the case of the DSC2 A897fsX900 variant,
binding to PKP2 was comparable to DSC2a WT, while its afﬁnity
for PG was again reduced (Figure 6C).
In conclusion, we have identiﬁed a strong pathogenic potential for
the two missense mutations as well as moderate changes for the
DSC2 A897fsX900 variant. Moreover, all mutations could potentially
affect PG at the ID; however, we failed to detect altered PG localiz-
ation in NRC transfected with DSC2 R203C or T275M (Figure 6D).
Our ﬁndings suggest that the two missense changes in DSC2 may
indeed contribute to the pathogenesis of ARVC and in addition
might help to explain why the A897fsX900 variant may not be fully
penetrant.
4. Discussion
In the ID of cardiomyocytes, desmosomes provide a rigid connection
between neighbouring cells, allowing them to withstand mechanical
strain. In these structures, the desmosomal cadherins DSG2 and
DSC2 homo- and heterodimerize with their extracellular cadherin
domains, whereas their intracellular portions bind other desmosomal
components, i.e. PG and PKP2, which in turn link to DSP, which pro-
vides a link to the desmin cytoskeleton.
5
Mutations in these ﬁve cardiac desmosomal genes can cause
ARVC,
1,2 a disease associated with life-threatening arrhythmias and
high incidence of sudden cardiac death. Tissue analysis of Individual
Figure 2 DSC2 R203C and T275M display processing defects. (A) Position of the newly identiﬁed mutations and the A897fsX900 variant in DSC2a
(modiﬁed from Awad et al.
2). The cleavage site (scissors symbol) during proteolytic maturation is indicated, also the ﬁve extracellular cadherin
domains (EC), the transmembrane region (TM), and the cytoplasmic domain (cytopl). The position of the GFP tag used in some experiments is
also indicated. (B) Western blot of DSC2a WT and the R203C and T275M mutant proteins (using GFP fusion proteins), as well as of DSC2a WT
and the A897fsX900 variant (using tag-free constructs). The positions of pro-protein form (P) and mature protein (M) are indicated for DSC2
WT. (C) Quantiﬁcation of pro-protein to mature protein ratios by densitometry. The results of one representative experiment are shown as
mean ratio + standard deviation (in total, four independent experiments). Results of Student’s t-test: R203C vs. WT, P , 0.001; T275M vs. WT,
P , 0.05; A897fsX900 vs. WT, P ¼ 0.62 (not signiﬁcant).
DSC2 mutations causing ARVC 81Figure 3 Localization of DSC2 WT, R203C, T275M, and A897fsX900 in HL-1 cells. (A) Localization of the DSC2 WT, R203C, T275M, and
A897fsX900 proteins in transiently transfected HL-1 cells (red), counterstained with the cell–cell contact marker b-catenin (green), nuclei are visu-
alized with 4′,6-diamidino-2-phenylindole (DAPI, blue), and merged images (forth column). Indicated areas (white boxes) are also shown enlarged
below. Scale bars, 10 mm. DSC2 WT and A897fsX900 were primarily found at the desmosomes of cell–cell contacts (with some additional Golgi
apparatus and vesicular localization upon higher expression levels); however, DSC2 R203C was completely absent from cell–cell contacts,
whereas DSC2 T275M showed less efﬁcient targeting to these structures. (B) Quantiﬁcation of changes in cellular localization. Localization of trans-
fected HL-1 cells was divided into categories 1–5 (for examples of each category, see Supplementary material online, Figure S6). Cells (.200 per
construct per experiment) were counted and the percentage of each category was calculated. Combined data of three independent experiments
are shown. Signiﬁcant changes in cellular distribution compared with the same category for WT are indicated: *P , 0.05, **P , 0.01,
***P , 0.001; NS, not signiﬁcant.
K. Gehmlich et al. 8255.2 provided insights into potential mechanisms underlying arrhyth-
mias and sudden cardiac death: fibrosis (see Supplementary material
online, Figure S5A) is thought to cause electric isolation of cardiomyo-
cytes and may thereby facilitate reentrant excitation (discussed in
Gehmlich et al.
13). In addition, gap junction remodelling (as documen-
ted by loss of Cx43 signal from the IDs; see Supplementary material
online, Figure S5B) may contribute to conduction heterogeneity and
increase the risk of arrhythmic events.
13
Failure of appropriate localization of PG to the ID, irrespective of
the underlying genetic mutation, is a recently suggested feature of
ARVC.
7 We have conﬁrmed this observation for the ﬁrst time for a
DSC2 mutation (Figure 6A). This suggests that PG plays a major role
in the pathogenesis of ARVC. The mechanisms of how diverse
changes in different desmosomal proteins cause the same disease
however are poorly understood.
Here, we explore the consequences of ARVC-associated DSC2
mutations at the molecular level. Any mutation resulting in a prema-
ture stop codon before the transmembrane domain is predicted not
to produce any functional protein. Such null alleles, e.g. the newly
identiﬁed DSC2 L229X and DSC2 G371fsX378 mutations, as well
as previously reported ones,
15,17 act primarily through
haplo-insufﬁciency, and such a reduction of one desmosomal com-
ponent is likely to have deleterious effects on the entire structure,
as observed by electron microscopy for ARVC patients and DSC2
knockdown in a zebraﬁsh model.
15,28 In particular, 50% reduction of
DSC2 at the desmosomes reduces the number of ligands for PG
and PKP2 in the structures. DSC2 and DSG2 bind to PG and PKP2
with similar strength (Figure 5A), so lack of DSC2 could only be
partly compensated by DSG2. In addition, missense mutations in
DSC2 can also potentially affect desmosomal structure and integrity.
The two novel missense mutations investigated, DSC2 R203C and
DSC2 T275M, are located in the N-terminal cadherin domains. These
modules mediate the adhesive properties of the cadherins in a
calcium-dependent fashion, and the binding of calcium ions at the
interface of neighbouring cadherin domains is a pre-requisite for cad-
herin function.
29,30 Both affected residues (R203 and T275) are evol-
utionary conserved and structural models suggest crucial roles of
both mutated residues for the domain integrity (see Supplementary
material online, Figure S4B).
Both mutant proteins exhibit defects in processing into the mature
form (Figure 2; see Supplementary material online, Figure S2). Nor-
mally, this proteolytic process involves endoprotein convertases and
results in functional activation of DSC2, because in the precursor
form, the pro-protein extension prevents binding to other cadher-
ins.
31 In the case of DSC2 R203C, the mutant fails to undergo the
complete cleavage, whereas the DSC2 T275M protein can still be
processed, but shows a higher pro-protein to mature protein ratio
(Figure 2B and C; see Supplementary material online, Figure S2). As a
consequence, the non-functional DSC2 R203C fails to localize at
the desmosomes of ID structures, whereas only a proportion of
the partly functional DSC2 T275M protein is still incorporated into
the desmosomes (Figures 3 and 4).
In our study, Patient 35.1 is heterozygous for DSC2 R203C and
Patient 37.1 is homozygous for DSC2 T275M. In the former, 50%
of DSC2 is functional as there is only one DSC2 WT allele present.
In the latter, our experiments show that only two-thirds of the
DSC2 are processed into the mature form. Consequently, in both
cases, there is a signiﬁcant reduction of the mature, functional
DSC2 protein level at the ID. This further implies that lack of func-
tional DSC2 at the ID is primarily responsible for the disease pheno-
type rather than a dominant-negative action of the mutant proteins.
Partially, abnormal localization of two other ARVC-associated
DSC2 missense mutations has also been noted in cardiomyocytes.
12
The properties of the DSC2 A897fsX900 protein contrast with the
ﬁndings with the N-terminal mutations. This C-terminal mutation
changes the last ﬁve amino acids of the larger DSC2a splice
isoform, whereas the DSC2b isoform is unaffected (see Supplemen-
tary material online, Figure S1A). Our ﬁndings suggest that this
mutant protein is normally processed into its mature form and can
be incorporated into the desmosomes of HL-1 cells and cardiomyo-
cytes (Figures 3 and 4). In contrast to only minor changes in
Figure 4 Localization of DSC2 WT, R203C, T275M, and
A897fsX900 in NRC. (A) Localization of the DSC2 WT (top),
R203C (middle), and T275M (bottom) proteins in transfected
NRC (red), counterstained with the ID marker b-catenin (green),
and merged images (third column). Scale bar 10 mm. DSC2 WT
was primarily found at the ID structures. DSC2 R203C showed
only marginal targeting to the ID, but was primarily found in vesicles
throughout the cytoplasm. DSC2 T275M showed targeting to the
ID, but to a lesser extent, and was additionally found in vesicular
structures in the cytoplasm. (B) Localization of the DSC2 WT
(top) and A897fsX900 (bottom) proteins in transfected NRC
(red), counterstained with DSP as an ID marker (green), and
merged images (third column). Scale bar, 10 mm. The DSC2
A897fsX900 protein is normally targeted to the ID structures.
DSC2 mutations causing ARVC 83Figure 5 The DSC2a A897fsX900 variant is impaired in binding PG and DSP. (A) (Left) Binding of PG and PKP2 to desmosomal cadherins (DSC2a,
DSC2b, DSG2, and DSC2a A897fsX900) in GST-pulldown assays. A dilution (1%) of the rat heart lysate is shown (‘input’). A Coomassie-stained gel
shows the GST fusion protein inputs, together with a GST alone control (the position of the marker proteins is indicated on the right). Note that the
DSG2 GST-fusion preparation additionally contains degradation products. (Right) Quantiﬁcation of the bound protein by densitometry, relative to the
strongest interaction (set to 1.0), black columns indicate binding of PG and grey columns of PKP2 to the GST fusion proteins. (B) (Left) Reduced
binding of DSC2a A897fsX900 cytoplasmic domain to endogenous PG in COS-1 cells. GST fusion proteins of DSC2a WT and A897fsX900 were
expressed in COS-1 cells and assayed for binding to PG and PKP2 in GST-pulldown assays (PD). For comparison, lysate controls (LYS) of PG and
PKP2, as well as GST-DSC2a proteins are given (GST). (Right) Quantiﬁcation of the bound PG (black) and PKP2 (grey) protein by densitometry,
relative to DSC2a WT (set to 1.0). For the DSC2a A897fsX900 protein, binding to PG was dramatically reduced, whereas binding to PKP2 was
only mildly affected. (C) (Left) Reduced binding of DSC2a A897fsX900 cytoplasmic domain to DSP. GST fusion proteins of DSC2a WT and
A897fsX900 were co-expressed with DSP-NTP (fused to GFP) in COS-1 cells and assayed for binding in GST-pulldown assays (GST-Pd). For com-
parison, lysate controls for DSP-NTP, as well as GST-DSC2a proteins in the GST pulldown (GST) are given. (Right) Quantiﬁcation of the bound
DSP-NTP by densitometry, relative to DSC2a WT (set to 1.0). Binding of DSC2a A897fsX900 protein to DSP-NTP was reduced to  50%.
K. Gehmlich et al. 84localization observed in our experiments (Figure 3), a recent report by
De Bortoli et al.
18 suggested the mis-localization of this variant in
HL-1 cells. The use of a GFP fusion protein construct in their exper-
iments might artiﬁcially have obscured the real localization of the
mutant protein. We utilized the lack of cross-reactivity of our anti-
bodies with rodent proteins to study the behaviour of non-tagged
human constructs (exposing the different carboxy-termini) and
found only small changes in cellular localization.
Our GST-pulldown assays clearly demonstrate impaired binding of
the DSC2a A897fsX900 variant to PG and DSP (Figure 5), while
binding to PKP2 was virtually unaffected. This ﬁnding was conﬁrmed
by co-immunoprecipitation experiments using full-length proteins.
As observed before, the DSC2 A897fsX900 protein bound more
weakly to PG than DSC2a WT, while binding to PKP2 was normal
(Figure 6C). However, the effect seen here was not as dramatic as in
experiments using only the cytoplasmic portion, and this may be
explained by potential homo- or heterodimerization with desmoso-
mal cadherins via the N-terminal cadherin domains.
30
The DSC2 A897fsX900 variant has now been found in apparently
healthy individuals.
18 Although a low expression level of the DSC2a
Figure 6 The DSC2a mutations potentially affect PG at the IDs. (A) Confocal immunoﬂuorescence analysis of myocardial tissue from Patient 55.2
(heterozygous DSC2 G371fsX378 mutation). The PG signal is strongly reduced at the ID of Patient 55.2 in comparison to non-failing control tissue,
whereas the adherens junction protein N-cadherin can be abundantly detected at the IDs of both samples. Scale bar, 10 mm. For staining of other
desmosomal proteins, see Supplementary material online, Figure S5.( B) Reduced binding of DSC2a R203C to PG and PKP2 in COS-1 cells. Trans-
fected full-length DSC2a WT or R203C GFP was immunoprecipitated with a DSC2 antibody and bound PG and PKP2 detected; cell lysates are
also shown. (C) Reduced binding of DSC2a A897fsX900 to PG, but not to PKP2 in COS-1 cells. Transfected full-length DSC2a WT or R203C
(tag-free proteins) was immunoprecipitated as in (B) and bound PG and PKP2 detected; cell lysates are also shown. (D) PG localization (red) in
NRCs expressing DSC2a WT, R203C, and T275M (green). Scale bar represents 10 mm. In all three transfections, PG was found at the ID, regardless
of the localization of the DSC2 GFP fusion protein; the abundance of endogenous DSC2 WT protein may compensate any deleterious effect of the
DSC2 mutants.
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18 may contribute to the lack of an overt
phenotype in these individuals, our functional studies demonstrate a
pathogenic potential of this variant: its impaired binding to PG
cannot directly be compensated by the DSC2b isoform, which does
not bind PG (Figure 5A). However, the cytoplasmic domain of
DSG2 appears to have redundant functions in binding PG in the des-
mosomes. Currently, it is unclear whether carriers of the variant
exhibit subclinical features of disease expression or what the potential
is for disease development in individuals who perform endurance
training or carry other common variants. In the future, high-
throughput genomic analysis of large families and large, well-deﬁned
cohorts might help to answer these questions.
The striking observation of our functional studies is that—despite
their different individual properties—all the DSC2 mutant proteins
appear to affect PG at the IDs: for each of the mutations, the ability
of DSC2 to provide an anchor for PG is impaired. As a consequence,
PG may not be efﬁciently targeted to, or retained at, the desmo-
somes, and in turn might become available for other intracellular
pools. This loss of PG from the ID has been reported in ARVC
patients
7 (including individuals with DSC2 mutations, Figure 6A).
Beyond being a diagnostic feature, this event may be crucial in
disease pathogenesis: data from transgenic animal studies suggest
that unbound PG might be translocated into the nucleus and could
aberrantly modulate transcriptional pathways, especially by competing
with b-catenin in the Wnt-signalling pathways.
8,11 Our functional
studies on the three DSC2 mutations suggest for the ﬁrst time a mol-
ecular explanation how DSC2 mutations may contribute to the same
‘common ﬁnal pathway’ of ARVC.
In transfection experiments, we failed to observe a redistribution of
PG from the ID in the presence of the mutant DSC2 proteins
(Figure 6D), neither were changes in desmosomal composition
observed (see Supplementary material online, Figure S2). However,
these cellular systems may not be adequate to reﬂect the in vivo situ-
ation: in patients with heterozygous mutations, one functional WT
allele is replaced by a mutant DSC2 form, which affects PG binding.
In contrast, the mutant DSC2 proteins were expressed in addition
to the endogenous DSC2 in our experiments. Therefore, the abun-
dant endogenous DSC2 protein may compensate any deleterious
effects of the DSC2 mutants. As demonstrated for mutations in the
cytoplasmic region of DSG2,
13 additional indirect effects beyond
altered binding properties may contribute to the complexity of the
disease.
In the future, the reduction of functional DSC2 protein in a cellular
model systems (e.g. by RNA interference) will be a valuable tool to
study down-stream pathogenic events, such as the redistribution of
PG from the ID and aberrant activation of PG signalling in the
nucleus. Moreover, animal models engineered for the cardiac-speciﬁc
expression of DSC2 mutation forms will help to provide mechanistic
insights into ARVC.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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